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Abstract
Objective: Pompe disease (glycogenosis type II) is caused by lysosomal alpha-glucosidase 
deficiency, which leads to a block in intra-lysosomal glycogen breakdown. In spite of 
enzyme replacement therapy, Pompe disease continues to be a progressive metabolic 
myopathy. Considering the health benefits of exercise, it is important in Pompe disease 
to acquire more information about muscle substrate use during exercise.
Methods: Seven adults with Pompe disease were matched to a healthy control group 
(1:1). We determined (1) peak oxidative capacity (VO2peak) and (2) carbohydrate and 
fatty acid metabolism during submaximal exercise (33 W) for 1 h, using cycle-ergometer 
exercise, indirect calorimetry and stable isotopes.
Results: In the patients, VO2peak was less than half of average control values; mean 
difference −1659 mL/min (CI: −2450 to −867, P = 0.001). However, the respiratory 
exchange ratio increased to >1.0 and lactate levels rose 5-fold in the patients, indicating 
significant glycolytic flux. In line with this, during submaximal exercise, the rates 
of oxidation (ROX) of carbohydrates and palmitate were similar between patients 
and controls (mean difference 0.226 g/min (CI: 0.611 to −0.078, P = 0.318) and mean 
difference 0.016 µmol/kg/min (CI: 1.287 to −1.255, P = 0.710), respectively).
Conclusion: Reflecting muscle weakness and wasting, Pompe disease is associated with 
markedly reduced maximal exercise capacity. However, glycogenolysis is not impaired 
in exercise. Unlike in other metabolic myopathies, skeletal muscle substrate use during 
exercise is normal in Pompe disease rendering exercise less complicated for e.g. medical 
or recreational purposes.
Introduction
Pompe disease (Glycogenosis type II; OMIM #232300) 
is caused by lysosomal acid alpha-glucosidase deficiency 
(EC# 3.2.1.20), which leads to a metabolic block in intra-
lysosomal glycogen breakdown (1). In the late-onset forms 
of Pompe disease, morbidity and mortality are mainly 
caused by progressive skeletal muscle weakness and 
wasting (2). Even though treatment with recombinant 
acid alpha-glucosidase improves walking distance and 
lung function, and slows down disease progression rate 
and improves life expectancy, Pompe disease continues 
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to be a progressive metabolic myopathy (3, 4). Therefore, 
new treatments are continuously being investigated in 
Pompe disease. Exercise is one intervention, which has 
the potential to improve skeletal muscle function in late-
onset forms of Pompe disease (5).
Glycogen is an essential source of energy for skeletal 
muscle during exercise (6). Exercise may increase skeletal 
muscle energy requirements many fold, and therefore 
exercise may be used as a tool to unmask unrecognized 
derangements in muscle substrate turnover in patients 
with metabolic myopathies (5, 7, 8, 9, 10, 11, 12). 
Unmasking such derangements may be used to determine 
what types of exercises may be tolerated and whether or 
not substrate supplementation might improve exercise 
tolerance. Recently, it has been suggested that patients 
with Pompe disease are in a state of ‘chronic energy 
deficiency’ at rest (13). An energy deficiency at rest is 
likely to be exaggerated by exercise. However, substrate 
turnover during moderate intensity exercise has not been 
studied in patients with Pompe disease.
We therefore wanted to determine the maximal 
aerobic exercise capacity and to measure substrate 
turnover during prolonged (i.e. 1 h) moderate intensity 
exercise, in patients with Pompe disease. We used cycle-
ergometer exercise and stable isotope methodology in 
combination with indirect calorimetry to determine 
glucose, glycerol, and fatty acid metabolism during 
exercise, and we measured body composition with dual 
X-ray absorptiometry (DEXA) scanning, to determine the 
lean body mass.
Materials and methods
Subjects
We included 7 patients older than 18 years with genetically 
and biochemically verified Pompe disease. The patients 
were matched by gender, age and body mass index (BMI) 
to a sedentary healthy control group (1:1). Data from 3 
of the controls in this study have been used as reference 
material for another study of glycogen debrancher 
deficiency (12) (Table 1).
Study design, setting and outcomes
The study was a case-control designed study, performed 
on 2 consecutive days, in our exercise laboratory in 
Copenhagen. Subjects were tested from December 
2011 to January 2014. The primary outcomes of the 
peak exercise test were to assess differences in peak 
oxidative capacity and concentrations of plasma lactate 
after peak exercise in patients vs controls. The primary 
outcomes during submaximal exercise were differences 
in the average rate of oxidation (ROX) of carbohydrates, 
palmitate and non-esterified fatty acids (NEFA), and the 
rates of appearance of glucose and glycerol in patients 
vs controls.
Exclusion criteria
Patients with serious heart or lung conditions 
contraindicating exercise testing as well as concomitant 
disorders or participation in other trials, which might 
interfere with the metabolic studies, were disqualified 
from participation.
Dual-Energy X-ray Absorptiometry scanning (day 1)
A whole-body DEXA scan (Prodigy Advance, GE Healthcare 
Lunar, software version 14.10.022) was performed to 
determine the body composition of the subjects. The 
subjects arrived in the laboratory in the morning after 
3 h of fasting, and they drank 0.5 L of water 30 min before 
the DEXA scan, in order to be well hydrated before peak 
exercise testing. Prior to DEXA scanning, the subjects 
voided urine. The subjects were tested wearing underwear 
only. Quality control was performed with a QC Phantom, 
Lunar AI in water.
Peak exercise testing (day 1)
Following the DEXA scan, the subjects performed a 
graded exercise test to exhaustion on a cycle-ergometer 
(Excalibur Sport, Lode BV, Groningen, the Netherlands) 
to determine peak oxidative capacity (VO2peak), and 
plasma lactate and glucose concentrations at exhaustion. 
Blood samples were drawn before and immediately after 
exercise from an indwelling venous catheter. A 3-lead 
ECG and a pulse transmitter belt monitored heart rate, 
and pulmonary gas-exchange was measured with breath-
by-breath indirect calorimetry (Quark CPET, Cosmed Srl, 
Milan, Italy). Blood to measure plasma creatine kinase 
(CK) was sampled before exercise, and again the following 
day (with background samples).
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Whole-body substrate turnover during submaximal 
cycle ergometer exercise (day 2)
The subjects arrived in the laboratory in the morning 
after an overnight fast. Catheters were inserted in the 
cubital vein in one arm for stable isotope infusion and in 
a hand vein on the opposite limb for blood sampling. A 
heating pad was wrapped around the hand to arterialize 
the venous blood (14). Background blood and breath 
samples were collected, expired air being sampled in 
an airtight collection bag (Hans Rudolph, Inc., KS, 
USA) for measurement of 13CO2/
12CO2. Subsequently, a 
primed constant rate infusion of stable isotope tracers 
was started; [U-13C]-palmitate (0.010 µmol/kg/min, 
bound to albumin and primed by NaH13CO3, 1.0 µmol/
kg), [6,6-D2]-glucose (0.40 µmol/kg/min, primed by 
13 µmol/kg) and [1,1,2,3,3-D5]-glycerol (0.053 µmol/kg/
min, primed by 0.795 µmol/kg). Infusions were delivered 
by a Gemini PC2 pump (IMED, San Diego, CA, USA) 
and continued for 2 h before exercise began. Breath 
and blood samples were drawn simultaneously 20 min 
before exercise and then repeatedly every 10 min until 
the end of exercise. Ten minutes before exercise, the 
subject was seated on the cycle-ergometer, equipped 
with ECG electrodes and a pulse transmitter, and a facial 
mask connected to the indirect calorimetry system. 
Pulmonary gas exchange was measured for 2 min before 
blood and breath samples were collected. One minute 
before blood sampling, the facial mask was removed to 
allow for the washout and collection of breath for 13CO2 
measurements. At the onset of exercise, the infusion 
rate of isotopes was doubled to avoid marked decreases 
in tracer enrichments. Heart rate and rate of perceived 
exertion (RPE, visual analog (Borg) scale from 6 to 20) 
were recorded every other minute during exercise (15). 
The patients exercised at a workload corresponding to 
~60% of their VO2peak, whereas the controls exercised at 
the same absolute workload as the patients.
Analysis of blood samples
Blood was drawn in syringes containing heparin and was 
analyzed for lactate and glucose concentrations within 
10 min on an ABL-725 system (Radiometer, Copenhagen, 
Denmark). Enrichments of plasma glucose and 
glycerol and the glycerol concentration were analyzed 
simultaneously by liquid chromatography–tandem mass 
spectrometry (LC–MS/MS), modified according to Oehlke 
(16). 13CO2-breath enrichment and plasma palmitate 
enrichment and concentration were analyzed by gas 
chromatography–isotope-ratio mass spectrometry 
(Finnigan MAT, Bremen, Germany). NEFAs were analyzed 
with a spectrophotometry kit (NEFA-HR(2), Wako 
Chemical Gmbh, Germany). Insulin and catecholamines 
were measured at rest and after exercise with enzyme-
linked immunosorbent assays (Insulin ELISA kit, Dako, 
Glostrup, Denmark, and 2-CAT plasma ELISA kit, 
Labor Diagnostica Nord GmbH & Co) and a Modulus 
II Microplate Multimode Reader (Turner Biosystems, 
Inc., Sunnyvale, CA, USA). Blood to measure plasma CK 
was collected in lithium-heparin coated tubes and was 
analyzed by an enzymatic assay and spectrophotometry 
in the Clinical Biochemical Department.
Substrate turnover calculations
The rates of appearance (Ra) and disappearance (Rd) of 
palmitate, glucose and glycerol at rest and during exercise 
were calculated using the non-steady-state equations of 
Steele adapted for the use of stable isotopes (17).
R
F V C C E E t tn n n n n n
a
1 1 1
( mol kg min)
((  ) / 2) ((  ) / (  ))
µ / /
=
− × + × − −+ + +
((  / 2)1E En n+ + )
R R V C C t tn n n nd amol/kg/min = / (+1 +1µ − − −( ) × (( ) ))
Plasma palmitate ROX mol kg min
V TCO2
( / / )µ
                  =
× TR / 16
TTR  acetate correction factor 100
breath
palmitate
( )
× /
F = infusion rate (µmol/min/kg), E = enrichment 
(tracer to tracee ratio), C = concentration (µmol/L), n 
and n + 1 = adjacent samples, VCO2 = CO2 production 
(µmol/kg/min), TTRbreath = 
13CO2/
12CO2 ratio in 
breath, TTRpalmitate = 
13C/12C palmitate ratio in plasma, 
t = sample time (min), V = volume of distribution 
(palmitate = 0.04 L/kg, glucose = 0.145 L/kg and 
glycerol = 0.230 L/kg). An acetate correction factor was 
applied (rest = 27%; exercise = 78%) (18, 19).
Indirect calorimetry
Fat and carbohydrate oxidation rates were calculated using 
non-protein respiratory exchange ratio (RER) equations 
adapted for moderate intensity exercise (20).
Whole-body carbohydrate oxidation (ROX) in 
g/min = 4.210 × VCO2 − 2.962 × VO2.
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Whole-body fat oxidation (ROX) in 
g/min = 1.695 × VO2 − 1.701 × VCO2.
Total NEFA oxidation rates were calculated by 
converting the rate of total fat oxidation to its molecular 
equivalent with the assumption that the average molecular 
weight of triglyceride is 860 g/mol and multiplying the 
molar rate of triglyceride oxidation by 3 because each 
molecule contains 3 fatty acid residues.
Ethics and statistics
The study was conducted in accordance with the 
Declaration of Helsinki and was approved by the Regional 
Ethical Committee of the Capital Region of Denmark 
(#H-2-2010-008, with amendment #39559). The subjects 
gave written informed consent prior to inclusion. Median 
resting and exercise values (averages from the whole 
exercise period), and body composition measurements 
were compared between patients and controls with a 
Mann–Whitney rank sum test, and CK levels in the 
patients before and after peak exercise with a Signed rank 
test. A P value <0.05 was considered significant (two-
tailed testing). Results are reported as mean ± s.d. (unless 
otherwise stated), and with 95% Confidence Intervals 
(CIs) of the mean for the primary outcomes (calculated 
with an un-paired t-test). Data from a previous study were 
used to estimate sample size, and PS Power and Sample 
Size, version 3.0.0.43. was used to calculate the sample 
size for the primary outcomes (21, 22). Statistical analysis 
was performed with SigmaPlot version 11.0.
Results
Body composition
The patients tended to weigh less than controls, 64.6 (s.d. 
13.2) vs 75.8 (s.d. 15.2) kg; however, the two groups had 
similar BMIs (Fig.  1). Nevertheless, patients tended to 
have a higher % body fat and a lower % lean body mass 
than controls (Fig. 1), and, consequently, a similar total 
fat mass (patients 23.9 (s.d. 10.3) kg and controls 22.2 (s.d. 
6.1) kg, P = 0.805) and a lower lean tissue mass (38.2 (s.d. 
6.8) kg vs 50.5 (s.d. 11.9) kg, P = 0.073).
Peak exercise testing
The peak work load, Wpeak, was lower in the patients than 
in controls, 92.9 W (s.d. 48.4; range: 50–150) vs 264.3 W 
(s.d. 70.2; range: 160–370), P < 0.001). In accordance 
with this, the patients’ absolute VO2peak was less than 
half of average control values (Fig. 2), and even though 
the patients tended to weigh less, adjusting the VO2peak 
for body weight (fitness rating) only minimally affected 
this difference: The fitness rating of patients was 28.8 mL/
kg/min (s.d. 8.9; range: 17.7–43.7) vs 43.4 mL/kg/min 
(s.d. 6.4; range: 35.7–52.6) in controls, P = 0.007. Lactate 
levels at rest were similar between groups; however, at 
time of exhaustion, blood lactate levels had increased 
significantly less in the patients (Fig. 2). The blood glucose 
levels were similar at rest (5.3 mmol/L (s.d. 0.8; range: 
4.2–6.4) and 5.3 mmol/L (s.d. 0.6; range: 4.9–6.6)) as well 
as after peak exercise (5.9 mmol/L (s.d. 1.2; range: 4.8–7.2) 
and 6.1 mmol/L (s.d. 0.6; range: 5.4–7.2)) in patients and 
controls, respectively.
The RER increased to ≥1.0 in all subjects during peak 
exercise, and there was no difference between patients, 
1.11 (s.d. 0.07; range: 1.00–1.22) and the controls, 1.11 
(s.d. 0.07; range: 1.02–1.23) at time of VO2peak (P = 1.00). 
The day after peak exercise, the average plasma CK level 
had not increased. However, in patient no. 6, who had the 
highest baseline CK level, CK increased by 33% (Fig. 2). 
Average heart rate at rest (79.6 (s.d. 16.0) vs 72.6 (s.d. 11.1) 
beats/min, P = 0.535) and at time of exhaustion (176.0 
(s.d. 18.2) vs 179.6 (s.d. 7.6) beats/min, P = 1.000) did not 
Figure 1
Body composition and BMI. (A) Body composition 
in patients and controls. The patients tended to 
have a higher percentage of body fat, 37.5 (s.d. 
11.5) %, compared to controls, 30.7 (s.d. 6.4) %, 
(P = 0.097), and in accordance with this a lower 
lean tissue mass 38.2 (s.d. 6.8) kg vs 50.5 (s.d. 11.9) 
kg in controls (P = 0.073). (B) There was no 
difference in the body mass index (BMI), between 
patients 22.4 (s.d. 4.5) kg/m2 and controls 24.8  
(s.d. 3.6) kg/m2, (P = 0.318). Error bars are s.d.
A B
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differ between patients and controls. Correspondingly, 
perceived exertion was maximal in all subjects.
Metabolism during constant-load 
submaximal exercise
Exercise conditions All subjects completed the 60 
min of cycle ergometer exercise, and the patients and the 
controls carried out the same absolute workload, 33.0 
(s.d. 17.9; range: 15–60) vs 31.4 (s.d. 16.8; range: 10–50) W, 
respectively (P = 0.902). Correspondingly, during exercise, 
the average oxygen consumption did not differ between 
patients, 1021 mL/min (s.d. 181; range: 867–1343) and 
controls, 972 mL/min (s.d. 208; range: 707–1317; 
P = 0.805). The relative workload, however, was higher for 
the patients (P < 0.001), being 63.8% (s.d. 7.9; range: 
53.9–76.2) of VO2peak vs 30.2% (s.d. 5.7; range: 23.0–39.8) 
for controls. In line with the exercise being relatively 
harder for the patients, during exercise, average heart rate 
was higher in the patients, 121 (s.d. 20.0; range: 99–147) 
vs 92 (s.d. 9.9; range: 87–106) beats/min in controls 
(P = 0.007), and the patients also rated exercise as being 
harder, 12.1 (s.d. 1.5; range: 10.0–14.3), than the controls 
did, 8.5 (s.d. 1.5; range: 7.0–10.9), Borg score (P = 0.001). 
A D
B E
C F
Figure 2
Peak exercise testing, plasma creatine kinase levels and hormones. (A) Peak oxygen uptake was significantly lower in the patients; mean difference 
−1659 mL/min (CI: −2450 to −867, P = 0.001). (B) Plasma lactate levels increased less in the patients than in controls, after peak exercise; mean difference 
−3.5 mmol/L (CI: −5.8 to −1.2, P = 0.007). (C) Average plasma CK levels, assessed in 5 patients, did not increase after peak exercise, 600 (s.d. 411) baseline vs 
692 (s.d. 552) U/L 1-day post exercise, mean difference of 91 U/L (CI: 295 to −112, P = 0.188) (P = 0.28). (D) Insulin levels were within normal range, both at 
rest and after 1 h of submaximal exercise, but levels were higher after exercise in patients vs controls; mean difference 17.9 pmol/L (CI: 1.3–34.5, 
P = 0.037). (E) Plasma epinephrine levels were significantly higher in the patients after 1 h of exercise; mean difference 844 pmol/L (CI: 412–1276, 
P = 0.001). (F) In line with this, plasma norepinephrine levels were also increased in the patients; mean difference 4392 pmol/L (CI: 1140–7643, P = 0.012). 
–, mean value; #significantly different from controls, P < 0.05.
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Plasma palmitate enrichment reached similar levels at 
the same time (20 min before exercise) in both groups, 
216 (s.d. 29) and 200 (s.d. 34) δ13C/δ12C (P = 0.736) in 
controls and patients, respectively, indicating that 
distribution volumes did not differ between groups 
(Figs 3 and 4).
Carbohydrate metabolism during constant-load 
submaximal exercise
During exercise, the rates of appearance and disappearance 
of glucose, i.e. liver glucose output and tissue glucose 
uptake, were similar within and between patients and 
controls, and, accordingly, blood glucose levels were 
similar between groups and remained stable throughout 
the full hour of exercise (Fig.  3). The average oxidation 
rates of carbohydrate were similar between patients and 
controls during exercise.
Fatty acid and glycerol metabolism during 
submaximal exercise
During exercise, the rate of oxidation (ROX) of palmitate 
and NEFAs were similar in patients and controls, and 
plasma palmitate and NEFA concentrations increased 
similarly in both groups. In agreement with this, the rate 
of appearance of glycerol, reflecting rate of lipolysis and 
rate of disappearance of glycerol (6.610 (s.d. 2.499) µmol/
kg/min in patients and 5.814 (s.d. 1.622) µmol/kg/min 
in controls, P = 0.620), reflecting tissue uptake, did not 
differ between the groups. Plasma glycerol concentration 
increased during exercise to ~1/3 of NEFA levels, which 
is in accordance with 3 fatty acids being released from 
A
B
C
D
Figure 3
Carbohydrate metabolism and blood lactate levels during submaximal exercise. (A) The whole-body carbohydrate (CHO) rate of oxidation (ROX) was 
similar between patients and controls during exercise; mean difference 0.226 g/min (CI: 0.611 to −0.078, P = 0.318). (B) The rate of appearance of glucose 
(Ra), i.e. liver glucose output, was also similar between patients 20.7 (s.d. 6.6) and controls 19.6 (s.d. 1.2) µmol/kg/min, respectively, during exercise; mean 
difference 1.1 µmol/kg/min (CI: 6.7 to −4.4, P = 0.902). (C) Blood glucose levels during exercise remained stable in patients 5.0 (s.d. 0.4; range: 4.5–5.6) and 
controls 5.5 (s.d. 0.6; range: 5.0–6.8) mmol/L, and there was no difference in blood glucose levels between groups (P = 0.128). (D) Blood lactate levels did 
not increase during exercise in controls; however, in the patients, the blood lactate levels rose significantly to a mean of 1.5 (s.d. 0.6) vs 0.6 (s.d. 
0.1) mmol/L in controls; mean difference 0.9 mmol/L (CI: 0.3–1.4, P = 0.001). Error bars are s.e.m. #significantly different from controls during exercise 
P < 0.05 (mean of whole exercise period).
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each triglyceride molecule undergoing peripheral adipose 
tissue lipolysis (Fig. 4).
Hormonal response to submaximal exercise
End-exercise insulin levels were higher in the patients, 
but levels remained within normal range. At the end of 
exercise, epinephrine and norepinephrine levels were 
significantly higher in the patients (Fig. 2).
Discussion
The present study shows that patients with late-onset 
Pompe disease, caused by lysosomal alpha-glucosidase 
deficiency, have a markedly impaired maximal aerobic 
exercise capacity. On the other hand, the patients are able 
to tolerate prolonged submaximal exercise for 1 h, which 
means that their endurance is normal (23). In contrast 
to other glycogenoses, in which markedly reduced peak 
A
B
C
D
E
F
Figure 4
Fatty acid metabolism and glycerol turnover during submaximal exercise. (A) Average palmitate oxidation rate (ROX) in patients during exercise, 2.396 
(s.d. 1.016) µmol/kg/min was similar to controls, 2.380 (s.d. 1.162) µmol/kg/min; mean difference 0.016 µmol/kg/min (CI: 1.287 to −1.255, P = 0.710). 
(B) Oxidation rates of non-esterified fatty acids (NEFA) per kilo body weight did not differ between patients 16.4 (s.d. 6.6; range: 6.2–25.7) and controls 
17.9 (s.d. 5.4; range: 13.1–29.3) µmol/kg/min (P = 0.805) during exercise. (C) The concentration of plasma NEFAs increased in patients 768 µmol/L (s.d. 466; 
range: 263–1496) and controls 734 µmol/L (s.d. 151; range: 493–963) (P = 0.710) during exercise. (D) ROX of fat 0.298 g/min (s.d. 0.109) did not differ 
between patients and controls 0.380 g/min (s.d. 0.095) (CI: 0.036 to −0.202, P = 0.209). (E) The rate of appearance (Ra) of glycerol, reflecting adipose tissue 
lipolysis, was similar between patients 7.065 µmol/kg/min (s.d. 2.728) and controls 6.168 µmol/kg/min (s.d. 1.791), during exercise; mean difference 0.897 
(95% CI: 3.584 to −1.790; P = 0.456). (F) Plasma glycerol concentrations were also similar during exercise in patients 217 µmol/L (s.d. 131; range: 417–55) 
and controls 172 µmol/L (s.d. 48; range: 108–260) (P = 0.456). Error bars are s.e.m.
This work is licensed under a Creative Commons 
Attribution-NonCommercial 4.0 International 
License.
DOI: 10.1530/EC-17-0042
http://www.endocrineconnections.org © 2017 The authors
Published by Bioscientifica Ltd
Research N Preisler et al. Metabolism in Pompe disease
En
d
o
cr
in
e 
C
o
n
n
ec
ti
o
n
s
6:392392–394
oxidative work capacity reflects impaired glycogenolysis 
(5, 8, 9, 24, 25), during maximal exercise, glycogenolysis 
was apparently adequate in the patients of the present 
study. Thus, at exhaustion upon graded exercise, blood 
lactate levels were high and the RER above ≥1, indicating 
100% carbohydrate combustion, as also found in 
controls. Rather than reflecting a metabolic block in 
substrate turnover, in Pompe disease, the impaired peak 
work performance is probably a direct consequence of 
the muscle wasting and weakness generally seen in the 
patients (5) and also demonstrated by body composition 
measurements (DEXA scanning) (Fig.  1) and clinical 
observations (Table 1) in the present study. The wasting 
likely reflects muscle fiber damage resulting from glycogen 
accumulation (26) as well as disuse (27). In line with this, 
baseline CK levels were slightly elevated, as it is expected 
in Pompe disease, reflecting the pathology of skeletal 
muscle damage in this myopathy (2, 26).
Impairment of glycogenolysis was not found during 
prolonged submaximal exercise in the patients with 
Pompe disease. Thus, at identical absolute workloads and, 
accordingly, energy needs, rates of total carbohydrate 
oxidation and plasma glucose turnover were similar 
in patients and controls (Fig.  3). Furthermore, during 
exercise in glycogenoses with significant blocks in muscle 
glycogenolytic capacity, i.e. Glycogenosis types IIIa, V, 
IXa and XIV, metabolism is shifted toward oxidation of 
fat (9, 11, 12), but in the present study, no compensatory 
increases in plasma palmitate and overall fat oxidation 
were seen in the patients (Fig. 4). On the contrary, during 
exercise, carbohydrate metabolism, in fact, tended to be 
higher in patients compared with controls as judged from 
the total carbohydrate oxidation rates and the fact that 
the blood lactate concentration increased only in the 
patients (Fig. 3). These findings correspond with the fact 
that the workload in relative terms (% of peak capacity) 
and, accordingly, plasma catecholamine concentrations 
(Fig. 2) (28, 29) were higher in patients than in controls.
During exercise, glycogen is mobilized from liver as 
well as muscle. Both tissues contain lysosomal alpha-
glucosidase as well as glycogen phosphorylase. However, 
the present findings, which were similar in patients 
with and without enzyme replacement therapy, confirm 
the view that during exercise glycogen phosphorylase 
rather than alpha-glucosidase is decisive for stimulation 
of glycogen breakdown in liver and muscle (11). In 
exercising human muscle, alpha-glucosidase is estimated 
to account for at most 8% of glycogen breakdown (30). 
Alpha-glucosidase activity has been shown to increase 
with exercise in trout liver, however, considerably less 
than glycogen phosphorylase activity (31).
After peak exercise, testing plasma CK concentration 
only increased in one patient, and endurance was normal 
in submaximal exercise. These findings indicate that 
moderate intensity aerobic exercise is safe in Pompe 
disease, and they extend observations from previous 
studies carried out at lower exercise intensities and 
durations (32, 33). Furthermore, our finding that unlike 
in other metabolic myopathies, skeletal muscle substrate 
use is normal during exercise, which renders exercise less 
complicated in Pompe disease.
Our patients were compared to a control group 
exercising at the same absolute workload as the patients, 
because a priori overall energy requirements and, 
accordingly, metabolism ought to be identical between 
groups (the 0-hypotheis). Comparisons between groups 
working at identical relative loads would be far more 
speculative, because relative work load is influenced by 
a multitude of internal and external factors, making 
the 0-hypothesis difficult to define. The dilemma of 
not being able to match controls to very weak patients, 
resulting in an inevitable difference in work capacity, is 
a common problem encountered in exercise studies of 
muscle diseases. The same relative workload in healthy 
subjects would have needed a much higher absolute 
workload and thus highly different energy turnover and 
substrate use in the controls, which in itself would skew 
the comparison. The relative work concept has been 
thoroughly elucidated in relation to physical training in 
healthy people (29, 35). While inactivity (i.e. too little 
training) may partly explain diminished V02max in various 
patient groups, also more specific disease characteristics 
may contribute making comparisons between patients 
and controls at identical relative loads difficult to 
interpret.
In conclusion, patients with late-onset Pompe disease 
have a markedly impaired maximal aerobic exercise 
capacity. On the other hand, the patients’ ability to 
endure prolonged submaximal exercise at a moderate 
intensity is normal, because, unlike in other metabolic 
myopathies, in Pompe disease skeletal muscle substrate 
use is normal during exercise. This supports the view 
that during exercise glycogen phosphorylase rather than 
alpha-glucosidase is decisive for stimulation of glycogen 
breakdown in liver and muscle. Our findings encourage 
use of regular exercise in Pompe disease for recreational 
purposes as well as for improving physical function 
and health.
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